Synchrony Financial has outperformed the broader market over the past year, and analysts are moderately optimistic about the ...

Bloomberg's large-cap BMVP portfolio delivered positive returns in 2Q but trailed its benchmarks, held back by its defensive tilt during one of the fastest market rebounds on record.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Con ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Jefferson Capital Systems, LLC vs. Carolyn Huddleston - debt claim Velocity Investments LLC assignee of Cross River Bank vs. Kayla Sageser - debt claim Citibank, N.A. vs. David Rios - debt claim ...

Akero Therapeutics ( ($AKRO) ) has released its Q2 earnings. Here is a breakdown of the information Akero Therapeutics presented to its investors.

Discover key insights from Stereotaxis' Q2 2025 earnings call. Explore innovation milestones, financial growth, and the road to commercial expansion.